摘要 |
The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit. |
申请人 |
LUDWIG-MAXIMILIANS- UNIVERSITAET MUENCHEN;MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.;BERTSCH, UWE;GIESE, ARMIN;KRETZSCHMAR, HANS;TAVAN, PAUL;HIRSCHBERGER, THOMAS;BIESCHKE, JAN;WEBER, PETRA;WINKLHOFER, KONSTANZE, F.;TATZELT, JOERG;HARTL, F., ULRICH;WUENSCH, GERDA;HOEGEN, TOBIAS, JOHANNES |
发明人 |
BERTSCH, UWE;GIESE, ARMIN;KRETZSCHMAR, HANS;TAVAN, PAUL;HIRSCHBERGER, THOMAS;BIESCHKE, JAN;WEBER, PETRA;WINKLHOFER, KONSTANZE, F.;TATZELT, JOERG;HARTL, F., ULRICH;WUENSCH, GERDA;HOEGEN, TOBIAS, JOHANNES |